Introduction
The first tumor-specific chromosomal aberration, a shortened chromosome 22 (22q-) or Philadelphia (Ph) chromosome, was observed in chronic myeloid leukemia (CML) (Nowell and Hungerford, 1960) . CML is characterized by a huge excess of Ph chromosome positive (Ph+) mature granulocytic cells and their precursors and is clinically divided in two phases. An initial chronic phase lasts on average 3-4 years, and usually progresses to a blast crisis characterized by nonregulated outgrowth of immature myeloid or lymphoid blast cells and a loss of differentiation. CML is a clonal disorder of a pluripotent hematopoietic stem cell. The Ph chromosome is an acquired abnormality and can be found in the hematopoietic cells of all lineages and their committed progenitors (for reviews see: Champlin and Golde, 1985; Koeffler and Golde, 1981; Greaves, 1982) .
The Ph chromosome is the result of a reciprocal translocation between the long arms of chromosomes 9 and 22 t(9;22)(q34;qil) (Rowley 1973; de Klein et al., 1982) . The breakpoints on chromosome 22 band qll occur in a small region of 5.8 kb, the breakpoint cluster region or bcr (Groffen et al., 1984) . Subsequent cloning experiments and DNA sequence analysis revealed that the bcr is part of a large gene, which has been called the bcr gene . The bcr contains four exons (bl-b4), and chromosomal breaks occur in two introns between exons b2, b3, and b4. Breakpoints on chromosome 9 are scattered over a distance of at leasl: 100 kb, but are all located 5' of the tyrosine kinase domain of the c-abl proto-oncogene (Heisterkampet al., 1983; Leibowitz et al., 1985; Grosveld et al., 1986; de Klein et al., 1986a) . As a result of the Ph translocation, the c-ablgelne is transferred from its normal position on chromosome 9 band q34 to the Ph chromosome. This event creates a head to tail bcr-abl juxtaposition on the Ph chromosome, with the bcr gene closer to the centromere (Heisterkamp eit al., 1983) . The fusion gene is transcribed into an 8.5 kb chimeric bcr-abl mRNA consisting at its 5'side of 3.2 kb bcr sequences linked to 5.3 kb of c-abl sequences, lacking the first exon of c-abl (Shtivelman et al., 1985 (Shtivelman et al., , 1986 Stam et al., 1985; Grosveld et al., 1986) . The hybrid RNA is translated into a hybrid protein product of 210 kd (p210bcr-ab') and exhibits an in vitro tyrosine kinase activity that can be distinguished from the enzymatic activity of the wild-type 145 kd c-abl protein (~145"~') (Ben-Neriah et al., 1986; Konopka et al., 1984 . The presence of the Ph chromosome w,as thought to be pathognomonic for CML. However, in 1970 Propp and Lizzi described a patient with acute lymphoblastic leukemia (ALL) with a high percentage of Ph+ marrow cells (Propp and Lizzi, 1970) . To date, it is reported that 25%-300/o of adult and 20/o-10% of childhood ALL are Ph+ (Sandberg et al., 1980; Priest et al., 1980) . It is surprising that Ph+ ALL and CML share the same marker chromosome, while they are clinically diffferent diseases. Either the two diseases are different expressions of one underlying malignant process, or the rnarker chromosome is not the same at the molecular level.
A factor obscuring the difference between Ph+ ALL and CML is the fact that following the chronic phase, 30% of the CML patients eventually develop a lymphoid blast crisis that closely resembles de novo Ph+ ALL (Catovsky, 1979) . In fact, cases have been reported1 that presented as a Ph+ ALL (de novo Ph+ ALL), but in which the DNA of the leukemic cells contained breaks within the bcr (bcr+) and expressed the 8.5 kb bcr-abl mRNA (de Klein et al., 1986b) . A plausible explanation for this phenomenon is that these patients have a lymphoid blast crisis following a silent or very short chronic phase of CML. In contrast to this, in three separate studies a total of eight cases of Ph+ ALL that lack rearrangements in i:he bcr (bcr-) and fail to express an 8.5 kb bcr-abl mRNA were described. No p2106cr-"bb' was found in the leukemic cells of these patients, but a novel c-abl protein of 190 kd was detected p,g@Jc'-ab'
(A) Summary of data of five patients with Ph+ ALL (patients A. E., F. Y., and P. N., also see Chan et al., 1987) . The Ph chromosome was observed by cytogenetic analysis in each case. Patient A. E. showed a complex variant translocation involving chromosomes 9, 17, and 22. Immunophenotyping of blast cells at presentation revealed a common ALL phenotype in all patients. The immunophenotype of patient A. E. after initialization of treatment showed coexpression of lymphoid and myeloid antigens. RNA analysis involved Northern blotting using c-abi kinase domain probes. Protein data are according to Chan et al. (1987) . ND, not determined. (6) Hypothetical classification of CML versus Ph+ ALL.
instead (Chan et al., 1987; Clark et al., 1987; Kurzrock et al., 1987) . Others showed that in Ph'bcr-ALL C-&J/ is consistently translocated to the Ph chromosome, and 3' bcr sequences are sometimes deleted (de Klein et al., 1986b; Erikson et al., 1986) .
We report here the underlying genetic mechanism in Ph+bcr-ALL. Chromosomal breaks still occur within the bcr gene, but they take place in the putative first intron of the bcr gene, which is 5'of the bcr involved in CML. In this way an alternative bcr-c-ablfusion gene is created, which is transcribed into a chimeric 7 kb bcr-abl mRNA. cDNA cloning and sequencing of the chimeric part of the 7 kb RNA of a Ph+bcr-ALL patient show that this was the product of an in-frame fusion of the bcr and c-abl open reading frames. Most likely the RNA encodes a Ph+ ALL-specific p190bcf-ab' hybrid protein since this product was shown to be present in another Ph+bcr-ALL patient with a chromosomal breakpoint in the first bcr intron. These findings establish the existence of two molecularly distinct Ph chromosomes in Ph+ ALL versus CML.
Results
Breakpoint Analysis of the bcr Gene in Ph+bcr-ALL This investigation was started with Southern blot analysis of the DNA from five Ph+ ALL patients S. D., A. E., F. Y., P N., and Tai (Table 1A ). The DNAs were digested with BamHI, Bglll, Hindlll, and EcoRl and hybridized with bcr cDNA probes covering the 5' two-thirds of the gene. No rearranged fragments could be detected, indicating that breakpoints map either farther 5', outside the bcr gene, or within large introns, escaping detection by the combination of probes and restriction enzymes used. To check for the presence of breakpoints in the chromosomal region encompassing the bcr gene, the DNA of patient S. D. was digested with the restriction enzymes Mlul and Sall. The fragments were separated by field inversion gel electrophoresis (Carle et al., 1986) . After blotting and hybridization, both digests showed rearranged fragments of 800 and 300 kb, respectively. The hybridization of rearranged fragments with both 5'bcr gene and c-abl cDNA probes (data not shown) indicates the presence of chromosomal breakpoints in the vicinity of the bcr and c-abl genes of patient S. D.
Cloning of a Novel Chimeric cDNA from a Ph+bcr-ALL Patient Northern blot analysis was performed with a c-abl cDNA probe (comprising the c-abltyrosine kinase domain) of the RNA from peripheral blood cells of Ph+bcr-ALL patient S. D. A relatively strong 7 kb mRNA and a weak 6 kb mRNA were detected ( Figure 1 , lane 2). It is clear from the comparison of the RNA to K562 RNA that the CML-specific 8.5 kb mRNA is not present in the leukemic cells of patient S. D. The same observation has been reported for other Ph+bcr ALL patients, although a novel p190c-ab' protein was expressed (Kurzrock et al., 1987; Chan et al., 1987; Clark et al., 1987) . If a new species of c-abl mRNA were present, encoding p190c-ab', then the-RNA comigrates on Northern blots with either the normal 7 kb or the 6 kb (types B and A, respectively) c-abf mRNA (Shtivelman et al., 1986) .
To analyze the structure of the c-abl mRNAs present in the leukemic cells of patient S. D. a hgtl0 cDNA library was constructed from the same RNA preparation used for the Northern blot analysis. The first strand cDNA synthesis was primed both with oligo(dT) and with a 17-mer oligonucleotide complementary to a sequence in the third c-abl exon. After synthesis of the second strand and EcoRl linker addition, a cDNA library of 2 x 106 pfu was generated. The library was screened with a 300 bp Saul-Hind11 c-abl cDNA fragment (comprising c-abl exon 2 and the 5' half of exon 3) mapping at the S'side of the 17-mer primer. Nine hybridizing plaques were found. Southern blot analysis of the EcoRI-digested DNA of these phages showed that the 1.6 kb insert of clone Dll hybridized not only to the c-abl Saul-Hind11 probe, but also to a 600 bp bcr cDNA fragment (EcoRI-BamHl) representing the 5'end of a fulllength bcr cDNA clone. In Figure 2 Shtivelman et al., 1985; 'Grosveld et al., 1986) , the first nucleotide should come from bcr. This predicts that the bcrexon involved contains a splice donor sequence at this position. To verify this prediction, we investigated the exon-intron border of the bcr exon corresponding to the most S'bcr part of the chirneric clone Dll.
From an EMBL3 genomic library, a phage clone that hybridized to the same 600 bp EcoRI-BamHI bcr cDNA probe (derived from the 5' end of the bcr gene) as clone Dll was isolated. The hybridization of the DNA in the phage appeared to be confined to a 7 kb EcoRl fragment, which was analyzed in detail ( Figure 4A ). Sequencing of the presumptive 3' border of the exon revealed a perfect splice donor site. The first nucleotide of the linking codon, a G-residue, is directly followed by the GT dinucleotide defining the 5' border of the intron ( Restriction enzyme and hybridization analysis showed the genomic bcr sequences to be colinear with bcr sequences contained in the cDNA clones Dll and KW3. KW3 is a full-length 8.5 kb bcr-abl cDNA clone derived from the CML cell line K562 (Lozzio and Lozzio, 1975) . Sl mapping analysis has not been performed, so the presence of small introns in this bcr exon may have escaped our attention. We anticipate that this 1.'7 kb of DNA is the first exon of the bcr gene. The restriction map of the 5' end of the exon was found to be colinear with the published bcrcDNA maps up to an Nael site, representing the possible 5'end of the gene Hariharan and Adams, 1987) . To simplify terminology, we will refer to 
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The first strand was primed with the phos-1.6 kB Sau I Kp" 1 phorylated Vmer, 5'-pATACTCAGCGGCATTGC -3'complementary to a sequence in c-ablexon a3. Details of the cDNA cloning procedures are described in Experimental Procedures. The restriction sites in Dil for Ml, BarnHI, Xhol, &JRI, this exon and the following intron as the first exon and intron of the bcr gene. The fine mapping data of clone Dll reveal that Dll has terminated 120 bp before the supposed bcr AUG start codon (Figure 4) . Therefore, we sequenced the first 170 bp of the open reading frame of the genomic exon (as indicated in Figure 4A ). Comparison of this genomic open reading frame sequence to the bcrcDNA sequence of this region Hariharan and Adams, 1987; our unpublished'results) shows exact colinearity. Thus, it is likely that translation of the chimeric RNA of patient S. D. initiates at the putative bcr start codon.
In Ph+bcr-ALL, Chromosomal Breakpoints Occur in the First lntron of the bcr Gene Cloning and mapping of the genomic bcr gene reveals a minimum size of 90 kb for this gene N. H., unpublished results) . This establishes the bcr gene to be large. The EcoRl restriction map is depicted in Figure 5A . The precise assessment of its size awaits cloning of a gap in the first intron. This first intron covers at minimum 30 kb of DNA.
The structure of cDNA clone Dll predicts that the chromosome 22 breakpoint in Ph+ ALL patient S. D. occurs in this first intron. At the 3' end of the intron (Figure 5l3 ), a cluster of recognition sites is found for the most commonly used restriction enzymes in our Southern blot analysis (EcoRI, BamHI, Bglll, and Hindill). The cluster prevents the detection of breakpoints mapping to the 5' side of it with cDNA probes. Using a 0.59 kb Pstl-Kpnl intron probe located at the S'side of this cluster ( Figure 5B ), we could detect rearranged fragments in two patients (P N. and Tai, Figure 6 ). The Southern blot in Figure 6 was hybridized twice. The first time, a 660 bp Pstl-BamHI bcrcDNA probe mapping just 3'of the first bcr intron failed to detect extra bands ( Figure 6 , bands without size indication or arrows). The second hybridization was performed both with this 660 bp bcr cDNA probe and with the 590 bp Pstl-Kpnl intron probe. This time rearranged fragments appeared, which are indicated by arrows in Figure 6 (the sizes of the normal genomic fragments detected by the 0.59 kb Pstl-Kpnl intron probe are indicated).
Patient P. N. is a Ph+bcr-ALL patient expressing p190c-ab' (Chan et al., 1987) and patient Tai was initially diagnosed as a Ph+ CML who relapsed after treatment and remission, with a bcr-ALL lacking the Ph chromosome. The Southern blot is from this Ph-period and shows that while cytogenetically no Ph chromosome is observed, there is a breakpoint in the first intron of the bcr gene. In patient S. D. we have been unable to detect chromosomal breakpoints with the 0.59 kb probe. Considering the structure of the cDNA cloned from this patient, the breakpoint should map elsewhere in this large intron, at a position that is not covered by the present analysis. We speculate that the same is true for two other patients, in whom we fail to detect achromosomal breakpoint (Table 1A) . Confirmation awaits Southern blot analysis with new probes that scan the entire intron for the presence of breakpoints.
Discussion
The results presented here provide direct evidence for a unique bcr-abl fusion in de novo Ph+ ALL. Surprisingly, the bcr gene is still involved in this Ph translocation, although Ph+bcr-ALL is clinically distinct from CML. The bcrgene on chromosome 22 appears to be large, covering at minimum 90 kb of genomic DNA. Chromosomal breaks in Ph+bcr-ALL occur in the putative first bcr intron (spanning at least 30 kb), which is 5'of the bcr involved in CML. . A detailed map of the most 5' EcoRl fragment of 7 kb containing the first exon of the bcr gene is presented in Figure  4 . The slashes indicate a gap in the cloned sequences. Arrows indicate breakpoints. Our data indicate that chromosomal breakpoints in differis clear that there should be a breakpoint present in this ent patients can be scattered over the intron; for example, large intron. It will be useful to generate a set of single in patient S. D. it was not possible to detect the breakpoint copy probes that monitor the entire large first intron for the with the available probes; however, from the structure of presence of chromosomal breakpoints in Ph*bcr-ALL the chimeric cDNA clone Dll isolated from this patient, it patients. It may provide a second means to define these 1 2 3 4 5 6 7 8 Figure 6 . Southern Blot of Two Leukemia Patients with a Break in the First lntron of the bcr Gene DNA of leukemic cells was digested with EcoRl (lanes 1 and 2), Bglll (lanes 3 and 4), Hindlll (lanes 5 and 6), and BamHll (lanes 7 and 8), separated on a 0.7% agaro!;e gel, transferred to nitrocellulose, and hybridized to the 590 bp first intron Pstl-Kpnl probe described in Figure  58 . Lanes 1 and 3, NALM 6 (cell line derived from a Ph-ALL; Hurwitz et (al., 1979) . Lanes 2 and 4, patient P N.; lanes 5 and 7, patient Tai; lanes 6 and 8, patient G (Ph.-CML). Arrows indicate abnormal bands. Sizes of unrearranged bands detected by the 590 bp Pstl-Kpnl probe are in kb.
patients on a molecular basis, particularly in cases in which in vitro phosphoprotein analysis for the presence of p190c-8b' cannot be performed. The first bcr intron breakpoint analysis could help in diagnosis to discriminate between a lymphoid blast crisis of CML and de novo Ph+bcr-ALL. This discrimination is difficult because clinically both leukemic states are similar: they have an extremely poor prognosis and the leukemic cells have a similar blast morphology. Moreover, the cells express the same composite immunophenotype of B cell precursors (Janossy et al., 1977; Greaves, 1982) with clonal rearrangements of Ig-H genes (Ford et al., 1983) . The criteria used to date are not always conclusive; in Ph+ ALL some Ph-cells can be present in the bone marrow, Ph+ cells can be eliminated from the marrow by therapy (as judged by cytogenetic analysis), and nonrandom chromosomal abnormalities in addition to the Ph chromosome are seen only rarely compared with the blast crisis of CML, in which they are common (Sandberg et al., 1980) . In one of the ALL patients (Tai) no Ph chromosome was detected, while the Southern blot showed a breakpoint in the first bcr intron. This underlines a role for molecular diagnosis in the clinical management of ALL, as the presence of a Ph chromosome drastically worsens the prognosis (Bloomfield et al., 1986; Priest et al., 1980) . Although we favor the idea that all chromosome 22 breakpoints in Ph+bcr-ALL patients will be found in the first bcr intron, the data do not exclude that they can also occur 5'of the bcrgene, in another as yet unidentified gene. This question will be resolved by Southern blot analysis of a larger number of Ph+bcr-ALL patients using the appropriate probes.
A new chimeric bcr-abl cDNA was cloned using RNA from the leukemic cells of a 2 year old Ph+bcr-ALL patient. The cDNA shows an in-frame joining of the first exon of the bcr gene and the second c-abl exon. Joining of the two exons occurs via normal splicing of the precursor mRNA using the splice donor site of the bcr first exon and the splice acceptor site of the c-abl second exon. The supposition that the bcr exon indeed represents the first exon of thebcrgene is based on circumstantial evidence: all 5'bcr cDNAs cloned to date have their 5'termini in a stretch of 300 bp (Hariharan and Adams, 1987; Mes-Masson et al., 1986 ; our unpublished results). These sequences, together with the bcr moiety of cDNA clone Dll, are contained in one probably continuous exon of 1.7 kb. The total size of the chimeric mRNA in patient S. D. is calculated to be 7 kb (1.7 kb of bcr and 5.3 kb of c-abl sequences). Thus on Northern blots this RNA will comigrate with the normal 7 kb type El c-abl and the 7 kb bcr mRNAs and will be difficult to identify by this analysis. In two reports on Ph+bcr-ALL (Clark et al., 1987; Kurzrock et al., 1987) aberrant c-abl transcripts of 6.5 and 7.4 kb were found, respectively. This could be the result of sizing problems on the Northern blots. Alternatively, since Clark et al. did not detect hybridization of the 6.5 kb transcript to a probe derived from the 5' part of the bcr gene, it may be that as yet unidentified genes are fused to the c-ablgene in these cases. Further analysis will clarify these discrepancies.
The chimeric RNA encodes a bcr-c-abl fusion protein of 1530 amino acids (426 bcr amino acids [Hariharan and Adams, 19871 and 1104 c-abl amino acids [Shtivelman et al., 19861) which is 476 or 501 amino acids residues shorter than the p210bcr--ab' fusion protein in CML (depending on the presence or absence of bcr exon b3; Heisterkamp et al., 1985) . We propose that the new fusion protein represents the p190c-ab' immunoprecipitated with abl antibodies and specifically found in Ph+ ALL (Chan et al., 1987; Kurzrock et al., 1987; Clark et al., 1987) . The 500 amino acid difference between p210bcr-ab' and pt9Oc"b' is not reflected in their mobility on SDS-PAGE gels, i.e., p190c-ab' runs too slowly. This may be due to the c-abl moiety of the protein, since the molecular weight of the normal c-abl proteins measured by this method is 145 kd, while these two proteins consist of only 1130 and 1148 amino acids, respectively. Besides the cloning of the cDNA from patient S. D., support for this supposition comes from patient P. N., who contains a breakpoint in the first bcr intron and was shown to express p190c-ab' (Chan et al., 1987) . The second patient (Tai) shows rearranged bcr gene fragments with the 0.59 kb Pstl-Kpnl first intron probe that comigrate with rearranged bands in BamHl and Bglll digests hybridizing with a 0.52 EcoRl probe (Chan et al., 1987 ) located 17 kb upstream of the c-abl second exon (L. M. W., unpublished results). This strongly indicates the presence of a chimeric bcr first exon-c-abl gene in patient Tai Final proof for the existence of a p190bcr-ab'awaits the development of antibodies directed against peptides encoded by the first bcr exon, studies now in progress. In concordance with the proposed structure for pt9Obcr-ab' in Ph+ ALL is the observation that the available antisera against the bcr gene do not precipitate p190bcr-ab', as they are not directed against peptides derived from the first exon of the bcr gene (Clark et al., 1987) .
The data suggest the existence of two molecularly distinct Ph chromosomes in CML and Ph+ ALL, the first containing chromosome 22 breakpoints in the 5.8 kb bcr and the second containing breakpoints in the first intron of the bcr gene (Table lB) , giving rise to different bcr-ablfusion proteins. At present, it is unclear whether there is a strict correlation between the two types of Ph chromosomes and the two different leukemias. There are cases initially scored as Ph+ ALL that show breakpoints in bcr and express the 8.5 kb chimeric mRNA. Most likely those cases represent lymphoid blast crises of CML, in which the chronic phase of the disease escaped detection (de Klein et al., 1986b) . On the other hand, there are indications that fusion of the first exon of the bcr gene to c-abl may not be restricted to Ph+ ALL. In two cases of chronic phase of typical CML no chromosomal breakpoints were detected with either probes covering the 5.8 kb bcr or full-length bcr cDNA probes. Moreover no 8.5 kb bcr-abl mRNA was found (L. Selleri, personal communication). In addition, patient Tai was initially diagnosed as having CML, but relapsed with ALL after treatment. The breakpoint detected in the first bcr intron in the ALL phase may have been present in the CML phase as well.
Although there may be exceptions, we expect that the presence of p190c-abf will be largely restricted to Ph+ ALL (Table 1B) . Therefore, the presence of this molecule is associated with an acute leukemia in which there is autonomous growth of immature invasive lymphoid blast cells, while p210bcr-aq' in CML is present in an initially nonagressive tumor with an excess of apparently normal myeloid cells of all differentiation stages. The acquisition of the Ph chromosome in CML is strongly correlated with the chronic phase of the disease. However, no consistent quantitative changes of the 8.5 kb bcr-abl mRNA are detected in the chronic phase versus the blast crisis in CML (Shtivelman et al., 1987) . Thus it is thought that the onset of the blast crisis originates from a second event unrelated to a bcr-abl joining. In concordance with this is the fact that a blast crisis of CML is usually accompanied by additional nonrandom chromosomal abnormalities such as trisomy 8 or 19 or isochromosome 17q (Champlin and Golde, 1985) .
De novo Ph+bcr-ALL also contains a bcr-abl fusion product, but lacks a chronic phase. Either a second hit escapes undetected, or the p190bcr-ab' has a transforming capacity that is considerably stronger than that of p210bCr-ab! Deletion of 476 or 501 bcr amino acids in p190bCr-ab' compared with p21@cr-'-ab' removes a part of the bcr protein that may be involved in controlling the action of the c-abl moiety of the protein. This hypothesis has to be tested in vivo, as there is no direct correlation between tyrosine phosphorylation activity in vitro of the different abl proteins and their transforming capacity in the target cell. Although the tyrosine kinase activity of ~210b~~-~~'is very similar to that of p160V-ab' , expression under several promoters (SV40, M-MuLV LTR, and bcr promoter) of the 8.5 kb full-length bcr-abl cDNA fails to transform NIH 3T3 fibroblasts, while the M-MuLV-LTR-driven v-abl gene does induce transformation (our unpublished results).
introduction of full-length 7 kb and 8.5 kb bcr-c-abl cDNAs under control of the bcr gene promoter into the germ line of mice may offer an in vivo system to test for the difference in transforming properties between p2jobcr-abl and plgobcr-abf,
Experimental Procedures
General Methods
Nucleic acid probes were labeled by the method of Feinberg and Vogelstein (1983) . Sequence analysis was done by the chain termination method (Sanger et al., 1980) , using single-stranded DNA derived from pTZ18/19vectorsaccording to the suppliers protocol (Pharmacia), or the chemical degradation method (Maxam and Gilbert, 1980) . Genomic libraries were generated in EMBL-3 or cosmid vectors as described by Grosveld et al. (1986) and de Klein et al. (1986) . RNA extraction was done as described by Chirgwin et al. (1979) or Auffray and Rougeon (1980) . Oligo(dT) column chromatography was performed according to Aviv and Leder (1972) , and a IFmer oligonucleotide was prepared on an Applied Biosystems 381A DNA synthesizer. Field inversion gel electrophoresis was performed according to Carle et al. (1986) . The programmable power inverter was purchased from MJ Research Inc.
cDNA Cloning Total RNA (50 pg) extracted from peripheral blood cells of patient S. D. was treated with RNAase-free DNAase (Promega). The RNA was denatured in 10 mM methylmercuric hydroxide. Priming was performed with oligo(dT) (12-18), and a c-abl third exon-specific phosphorylated l%mer, 5'-pATACTCAGCGGCATTGC-3'.
First strand synthesis was done with cloned M-MuLV reverse transcriptase (BRL); second strand synthesis was according to the RNAase H method (Gubler and Hoffman, 1983) . Blunt ends on the cDNA were generated with T4 polymerase, followed by internal EcoRl site methylation with EcoRl methylase (Sigma). In between reactions, the cDNA was purified on Elutip-D columns (Schleicher and Schuell). EcoRl linkers were ligated onto the cDNA with T4 ligase and RNA ligase (M,sniatis et al., 1982) , and after EcoRl digestion, the cDNA was size-selected on a Sephacryl S-1000 column. cDNA larger than 1 kb was ligated into the EcoRl site of hgtl0 (Huynh et al., 1984) . Phage DNA was packaged using packaging extracts (VCS).
